PMID: 6159960Dec 1, 1980Paper

DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma

Cancer
H F SeiglerA T Huang

Abstract

Treatment of 91 consecutive patients having metastatic, Stage IV melanoma who had not received any previous chemotherapy was begun between January 1977 and April 1978. The therapy included bleomycin (B) at 7.5 units subcutaneously in the first course and 15 units in subsequent courses on days 1 and 4; vincristine or Oncovin (O) at 1 mg/m2 intravenously on days 1 and 5; CCNU or lomustine (L) at 80 mg/m2 p.o. on day 1 and DTIC (D) 200 mg/m2 intravenously on days 1 through 5. Evaluable patients (72) were those who had measurable tumours in the viscera and on the skin. Seven patients (9%) responded with complete tumor regression (CR), 22 (31%) with partial regression (PR) (50% or more tumor regression), 12 (17%) with stabilization of disease, and 31 (43%) with progression of the disease. Patients who responded with CR, PR, and stable disease (41 patients) had a median survival of 67 weeks, while those who did not respond (31 patients) had a median survival of 20 weeks (P < .0001). Overall median survival was 31 weeks. The bleomycin-Oncovin-lomustine-DTIC (BOLD) regimen is an effective alternative treatment for metastatic melanoma; there is good tumor response and prolongation of survival in the responding patients. Its overall toxi...Continue Reading

Citations

May 20, 1998·Seminars in Surgical Oncology·F E Nathan, M J Mastrangelo
Oct 1, 1990·Journal of Surgical Oncology·C L SlingluffH F Seigler
Jun 1, 1997·Medical Oncology·J Hansson
Dec 21, 2000·Current Oncology Reports·P A Philip, L E Flaherty
May 15, 2003·The Surgical Clinics of North America·Charles Komen Brown, John M Kirkwood
Apr 6, 2004·Facial Plastic Surgery Clinics of North America·Theodore F Logan
Oct 31, 2002·Seminars in Oncology·Emilio BajettaDavid Khayat
Apr 15, 2006·World Journal of Surgical Oncology·Gianlorenzo DionigiRenzo Dionigi
May 1, 1990·Annals of Surgery·C L SlingluffH F Seigler
Feb 1, 1990·Journal of the American Academy of Dermatology·V C Ho, A J Sober
Apr 25, 2006·Surgical Oncology Clinics of North America·Steven O'Day, Peter Boasberg
Apr 1, 1989·Gynecologic Oncology·E BrandJ S Berek
Jul 1, 1986·European Journal of Cancer & Clinical Oncology·N H MulderH S Koops
Jan 1, 1985·Medical and Pediatric Oncology·H K KohR W Carey
Dec 1, 1996·The Surgical Clinics of North America·A N HoughtonP B Chapman
Dec 5, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Claus GarbeAlexander Eggermont
Sep 1, 1989·The Journal of Laryngology and Otology·V CalabreseA Sonzogni
Dec 4, 2003·Expert Opinion on Pharmacotherapy·Marko B Lens, Tim G Eisen
Oct 26, 2007·Journal of the European Academy of Dermatology and Venereology : JEADV·D NashanA Enk
Jun 1, 1994·The Journal of Bone and Joint Surgery. American Volume·B C BarnesJ M Harrelson
Aug 27, 2005·Japanese Journal of Clinical Oncology·Ugo BottoniStefano Calvieri
Sep 1, 1984·International Journal of Dermatology·R M MacKie, D Young
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P B ChapmanJ M Kirkwood
Jun 20, 1988·The Medical Journal of Australia·P G Gill
Jan 1, 1986·Medical Oncology and Tumor Pharmacotherapy·L E Spitler

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.